Publication at First Faculty of Medicine |
2023
Abstract
Psoriatic arthritis (PsA) is a chronic autoimmune disease with manifestations involving the musculoskeletal apparatus (entheses, joints, axial skeleton), skin, and its adnexa (hair, nails), and other organ structures. PsA belongs to a heterogeneous group ofspondyloarthritis and is thought to affect up to 30% of patients with psoriasis.
PsA therapy includes non-pharmacological treatment, symptomatic treatment, conventional synthetic disease-modifying drugs, biological therapy with respective biosimilar variants (bsDMARDs), and targeted synthetic disease-modifying drugs (tsDMARDs), so-called smáli molecules. The newest group of drugs ušed in the treatment of PsA include tsDMARDs that inhibit selected janus kinases.